U.S. Markets closed

AstraZeneca PLC (AZN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
29.08-0.10 (-0.34%)
At close: 4:02PM EDT

29.09 +0.01 (0.03%)
After hours: 6:51PM EDT

People also watch
GSKNVSSNYLLYBMY
Full screen
Previous Close29.18
Open29.49
Bid0.00 x 0
Ask0.00 x 0
Day's Range29.05 - 29.56
52 Week Range25.55 - 35.60
Volume4,612,673
Avg. Volume4,914,512
Market Cap72.04B
Beta0.67
PE Ratio (TTM)21.78
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.90 (3.08%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters4 hours ago

    FDA expands use of AstraZeneca/Merck ovarian cancer drug

    The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer. The drug was previously approved for treating advanced ovarian cancer in women who had stopped responding to at least three earlier rounds of chemotherapy.

  • Reuters5 hours ago

    FDA approves expanded use of AstraZeneca ovarian cancer drug

    The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. The agency also approved a new two-tablet regimen for the drug, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer. The drug was previously approved for treating advanced ovarian cancer in women who had stopped responding to at least three earlier rounds of chemotherapy.

  • AstraZeneca Plc : AZN-US: Dividend Analysis : August 11th, 2017 (record date) : By the numbers : August 16, 2017
    Capital Cubeyesterday

    AstraZeneca Plc : AZN-US: Dividend Analysis : August 11th, 2017 (record date) : By the numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing AstraZeneca Plc with the following peers – Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc Sponsored ADR, Sanofi Sponsored ADR, Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Biogen Inc. and Celgene Corporation (BMY-US, PFE-US, MRK-US, GSK-US, SNY-US, LLY-US, JNJ-US, ABT-US, ... Read more (Read more...)